In the present study, we examined the eects of overexpression of the potential tumor suppressor gene IGFBP-rP1/mac25 on cell-cycle kinetics in prostate cancer cells. The majority of the high expressing IGFBP-rP1/mac25 cell population was located in the G1 and sub-G0/G1 peaks; synchronizing cells in G2/M with nocodazole demonstrated the high expressing IGFBP-rP1/mac25 clones were delayed in the G1 phase of the cell cycle. Unscheduled expression of cyclin A in the sub-G0/G1 peak occurred in the IGFBP-rP1/mac25 clones. Immunoblots showed decreased cyclin D1 and p21 and increased cyclin E, p16, and p27 in the high expressing IGFBP-rP1/mac25 clones compared to the control cells. Cyclin D1/cdk-4,6 and cyclin E/cdk-2 kinase activities decreased but cyclin A/cdk-2 kinase activity increased for the high expressing IGFBP-rP1/ mac25 clones compared to control cells. A pRb immunoprecipitation demonstrated more binding of E2F-1 to pRb in the high expressing IGFBP-rP1/ mac25 clones than in control cells. Finally, cell senescence, as assessed by senescence-associated b ± galactosidase, demonstrated signi®cantly more staining in the IGFBP-rP1/mac25 cells than control cells. These results suggest that IGFBP-rP1/mac25 alters the cell cycle kinetics of the M12 prostate cell line by delaying the cells in the G1 phase of the cell cycle. In addition, the appearance of cyclin A in the sub-G0/G1 phase of the cell cycle and the increased kinase activity of cyclin A/cdk-2 in the IGFBP-rP1/mac25 clones suggests that cyclin A is associated with the apoptotic cells.
Introduction
Originally termed mac25 in meningial and mammary cell lines, insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has also been called tumor cell adhesion factor (TAF), prostacyclin stimulating factor (PSF), or angiomodulin depending on cell context (Kato et al., 1996; Kishibe et al., 2000; Oh et al., 1996; Swisshelm et al., 1995) . IGFBP-rP1/mac25 was originally cloned as a gene that was decreased in meningioma cell lines compared to primary cultures of benign leptomeningeal cells (Murphy et al., 1993) ; it was subsequently cloned by dierential display as a senescence-associated gene from human mammary epithelial cells (Swisshelm et al., 1995) . We have demonstrated increased IGFBPrP1/mac25 expression in senescent human prostate epithelial cell cultures as well (Lopez-Bermejo et al., 2000) .
Investigators have demonstrated in various malignancies that IGFBP-rP1/mac25 is a potential tumor suppressor protein. In breast cancer, there is a loss of heterozygosity for the IGFBP-rP1/ mac25 gene and its expression increased during senescence as well as in response to retinoic acid (Burger et al., 1998) . In murine SV40-T induced hepatocellular cancer, IGFBP-rP1/mac25 is silenced by methylation (Komatsu et al., 2000) . We have demonstrated decreased expression of IGFBP-rP1/ mac25 in metastatic prostate cancer (Hwa et al., 1998) . Re-expression of IGFBP-rP1/mac25 in a metastatic human prostate epithelial cell line inhibited tumor formation in vivo when the transfected cells were placed in nude mice, and in vitro it resulted in an increased sensitivity to apoptosis, increased cell doubling time, decreased invasion, and altered cell morphology (Sprenger et al., 1999) . In order to understand how IGFBPrP1/mac25 exerts its eect on tumor suppression in the M12 prostate cell line, we examined cellcycle kinetics in M12 cells transfected stably with IGFBP-rP1/mac25.
Results

Stable transfection of pc-IGFBP-rP1 into M12 cells
As described previously (Sprenger et al., 1999) , M12 cells were transfected stably with the pc-IGFBP-rP1/ mac25 construct or the empty vector as a control (M12pc 1 and M12pc 2 ). After at least 12 passages, the clones were checked for expression of IGFBP-rP1/ mac25 using both Western and Northern blots (Figure 1 ). The high expressing clones (Ha-Hc) continued to over-express IGFBP-rP1/mac25 mRNA and protein.
SA-b-galactosidase assay
Between 16 and 32% of the IGFBP-rP1/mac25 high expressing cells stained positive for SA-b-galactosidase compared to 5% of the control cells (Figure 2 ). PC-3 cells, which do not stain positive for SA-b-galactosidase, were included as a negative control. The presence of SA-b-galactosidase staining is used as a marker of cells that can develop a senescence-like phenotype in vitro and subsequently may be expected to undergo tumor suppression by expression of senescence-associated tumor suppressor genes such as IGFBP-rP1/ mac25 (Chang et al., 1999) .
Flow cytometry on asynchronous cells
We performed¯ow cytometry on cells grown for 20 h in growth-factor free medium. Control cells (M12pc 1 and M12pc 2 ) resided pre-dominantly in the G1 phase (mean of 71%) (Figure 3a) , while the high expressing IGFBP-rP1/mac25 clones (Ha-Hc) appeared predominately in a sub-G0/G1 (apoptotic) peak (mean of 54.4%) with a smaller G1 peak (mean of 19%) and little to no G2/M peak ( Figure 3b) . We have previously shown that the high expressing IGFBPrP1/mac25 clones (Ha-Hc) undergo apoptosis by DNA fragmentation assays and PARP cleavage (Sprenger et al., 1999) . The percentage of cells in the sub-G0/G1 peak was signi®cantly lower (P50.0001) for the control cells versus the high expressing IGFBP-rP1/mac25 clones. Likewise, the percentage of cells in the G1 peak was signi®cantly higher (P50.0001) for M12pc 1 and M12pc 2 versus the HaHc clones.
Flow cytometry on synchronized cells
Cells were treated with nocodazole (diluted in plain RPMI) for 20 h and then analysed by¯ow cytometry. Nocodazole was selected as the synchronizing agent because it synchronizes cells in G2/M and should clearly demonstrate cells that are delayed in G1 (Ho et al., 2001) . M12 control cells had arrested in the G2/ M phase of the cell cycle, as would be expected (Figure 3c ). The high expressing IGFBP-rP1/mac25 clones, however, remained pre-dominately in the G1 phase (Figure 3d ). Cells were treated with nocodazole for 20 h and then released by replacing the nocodazole medium with de®ned medium (see Cell culture). Twelve hours after release, the control cells began to cycle back to the G1 phase; the high expressing IGFBP-rP1/mac25 clones, though, died leaving very Flow cytometry using cell cycle antibodies M12 control cells expressed high levels of cyclin D1 in the G1 and S phases of the cycle, while the highest expression of cyclin A was limited to the late S, early G2/M phase (Figure 4 ). In the high expressing IGFBPrP1/mac25 clones, cyclin D1 expression was primarily in the G1 phase whereas cyclin A expression appeared in the sub-G0/G1 peak (Figure 4 ).
Western immunoblots on cell cycle proteins
Western immunoblots were performed on synchronized cell lysates to examine dierences in protein levels in cells delayed in G1. No dierences in levels were detected in cdks -2, -4, or -6. The high expressing IGFBP-rP1/mac25 clones had decreased levels of cyclin D1 (63% of control) and p21 (mean of 48% of control) but had increased levels of cyclin E (mean of 270% of control), p16 (mean of 250% of control)k, and p27 (mean of 210% of control) in comparison to the M12 control cells ( Figure 5 ).
Cyclin-dependent kinase activity
Since PI¯ow cytometry on the cells suggested the IGFBP-rP1/mac25 clones were delayed in G1, we examined the kinase activities for cyclin D1/cdk-4,6, cyclin E/cdk-2, and cyclin A/cdk-2. The high expressing clones had decreased levels of phosphorylated pRb-GST fusion protein (59% of control) and reduced cyclin E/cdk-2 activity (37% of control) (Figure 6a, b) . Western analysis con®rmed that the immunoprecipitates generated with cyclin D1 and cyclin E antibodies contained cdk-4,6 and cdk-2, respectively. In contrast, cyclinA/cdk-2 kinase activity increased by 400% in the IGFBP-rP1/mac25 high expressing cells when compared to M12 control cells (Figure 6c ).
E2F-1 association with pRB
In order to determine if the decreases in cyclin D1/cdk-4,6 and cyclin E/cdk-2 activities were aecting E2F activity, we immunoprecipitated cell extracts with pRBantibody and performed a Western immunoblot with an E2F-1 antibody. For the IGFBP-rP1/mac25 clones, E2F-1 was associated with precipitated pRB and present in the supernatant, suggesting that most of the E2F-1 was not available for transcriptional activity ( Figure 7 ). For the M12 control cells, while some E2F-1 was bound to pRB, most of the E2F-1 remained unbound in the supernatant, suggesting that it was available for transcriptional activity.
Discussion
The M12 human prostate epithelial cell line was chosen to evaluate the mechanism of IGFBP-rP1/mac25 tumor suppression because (1) IGFBP-rP1/mac25 causes suppression of tumor growth and development in this cell line and (2) the M12 cells develop a senescence-like phenotype in vitro as indicated by expression of SA bgalactosidase. We previously reported that when the high expressing IGFBP-rP1/mac25 clones were injected subcutaneously into nude mice it suppressed tumor formation (Sprenger et al., 1999) . Because of this change in tumor formation, as well as changes in cell growth and morphology, we examined the cell cycle in these high expressing IGFBP-rP1/mac25 clones in comparison to the M12 cell line as a potential target for IGFBP-rP1/mac25 action.
Flow cytometry data from asynchronous cells demonstrated that M12 control cells underwent normal cell cycling as seen by the large G1 peak and smaller G2/M peak. On the other hand, the high expressing IGFBP-rP1/mac25 clones appeared to be undergoing apoptosis as indicated by the large sub-G0/G1 peak and the smaller G1 peak. When cells were synchronized with nocodazole, which causes cells to synchronize in G2/M,¯ow cytometry demonstrated that the control cells were able to move through the cycle and synchronize at the G2/M phase. However, the high expressing IGFBP-rP1/mac25 clones persisted in G1.
For the high expressing IGFBP-rP1/mac25 clones, FITC¯ow cytometry demonstrated that most of the cyclin D1 expression was speci®c for cells in the G1 population. Unlike tumor cells in which cyclin D1 is expressed throughout the cell cycle, in normal cells cyclin D1 synthesis and expression peaks at the start of G1 in response to mitogens and decreases as the cells progress through G1 Juan et al., 1996; Sherr, 1996) . A decrease in cyclin D1 synthesis can cause the cells to exit the cell cycle, at which point the cells can either become quiescent or undergo apoptosis (Sherr, 1996) . Zi and Agarwal, 1999 , demonstrated that cyclin D1 levels signi®cantly decreased in LNCaP cells arrested in G1. In addition, the G1 arrest was accompanied by a change in morphology in which cells became elongated with dendrite-like extensions; a similar morphological change was observed in the high expressing IGFBPrP1/mac25 clones (Sprenger et al., 1999) .
Immunoblots of cell cycle proteins further supported the concept that the high expressing IGFBP-rP1/mac25 clones were delayed in G1. Since cyclin E appears in the G1 phase of the cycle, very low levels of this protein would be expected at the G2/M phase. While the M12 control cells showed almost undetectable levels of cyclin E, the high expressing clones had high levels of this cyclin. Since very few cases of unscheduled cyclin E expression have been reported in cultured cell lines (Sherr, 1996) , the high expressing clones are probably not demonstrating unscheduled expression of cyclin E in the G2/M phase, but rather a delay in G1.
The increased levels of the cyclin-dependent kinase inhibitor p16 and decreased cyclin D1/cdk-4,6 activity in the high expressing IGFBP-rP1/mac25 clones also suggest a delay in G1. The cdk inhibitor p16 binds to cdk-4,6 so these kinases cannot form a complex with cyclin D1 thereby preventing the hyperphosphorylation of pRb. Immunoprecipitation of pRb subsequently showed greater binding of E2F-1 in the high-expressing IGFBP-rP1/mac25 cells compared to the M12 control cells. E2F transcription factors are necessary for progression through the cell cycle, thus having E2F remain bound to the hypophosphorylated Rb will also delay the cells in G1 (Sherr, 1996; Tsihlias et al., 1999 Tsihlias et al., , 2000 Weinberg, 1995) .
In replicative senescence of human prostatic epithelial cells, p16 increases while p21 decreases (Jarrard et al., 1999; Sandhu et al., 2000) . We have shown in a previous publication that p16 increases along with IGFBP-rP1/mac25 in senescing primary cultures of prostate epithelial cells in vitro (LopezBermejo et al., 2000) . The mechanism(s) for the increase in p16 and G1 arrest by senescence-associated tumor suppressor genes or by the senescence process has not been fully elucidated. However, it has been demonstrated in replicative senescence of human diploid ®broblasts that an increase in p16, hypophosphorylation of Rb, and G1 arrest can be induced by the introduction of the oxidant H 2 O 2 . We have reported that the high expressing IGFBP-rP1/mac25 clones have markedly increased expression of superoxide dismutase-2(SOD-2) (Plymate et al., submitted). SOD-2 converts O 7 to H 2 O 2 and may thus initiate the signaling cascade responsible for the delay in G1. We have further demonstrated that treating M12 control cells with H 2 O 2 results in phosphorylation of MAP kinase to levels seen in the high expressing IGFBP-rP1 clones (Plymate et al., submitted). Phosphorylation of MAP kinase is a reported mechanism for H 2 O 2 induced senescence and cell-cycle arrest Wartenberg et al., 1999) . Associated with the H 2 O 2 stimulation of MAP kinase and subsequent G1 cell-cycle arrest, Wartenberg et al. (1999) , has shown an increase in p27 kip expression, which inhibits cdk-2 kinase activity. We have demonstrated an increase in p27 protein in the high expressing IGFBP-rP1 clones along with a decrease in cyclin E/cdk-2 activity when compared to the M12 control cells.
Induction of senescence is usually associated with resistance to apoptosis; however, we have previously reported that IGFBP-rP1/mac25 expression in the M12 cell line results in increased sensitivity to apoptosis (Sprenger et al., 1999) . In the present study, we again demonstrate increased apoptosis. Interestingly, we found cyclin A/cdk-2 activity was increased in the high expressing IGFBP-rP1/mac25 clones. FITC¯ow cytometry demonstrated that expression of cyclin A in these clones appears in the sub-G0/G1 peak, suggesting unscheduled expression of this cyclin. An increase in cyclin A/cdk-2 activity has been associated with the early stages of apoptosis (Jin et al., 2000) . Proteolytic cleavage of the kinase inhibitor p21 is thought to result in this rapid increase in cyclin A/cdk-2 activity and resulting apoptosis (Adachi et al., 2001) . As we have shown, p21 is decreased in the high expressing IGFBP-rP1/mac25 clones. Therefore, a second mechanism for IGFBP-rP1/ mac25 suppression of tumor formation may be through the regulation of p21 and cyclin A/cdk-2 activity and the subsequent induction of apoptosis.
Although the classic concept is that SA-b-galactosidase expressing cells are senescent and do not undergo apoptosis, recent data suggest that human epithelial cells can evolve from the anti-apoptotic senescent state. Such cells still retain their SA-b galactosidase expression and replicative senescence, but adopt a more pleomorphic morphologic pattern and undergo apoptosis (Romanov et al., 2001) . The ability of a cell to develop a senescence-like phenotype is probably necessary in order for IGFBP-rP1/mac25, and its class of tumor suppressor genes, to exhibit its tumor suppressive activities. More importantly, it may also be an indication of the eectiveness of chemotherapeutic agents on a tumor cell (Campisi, 1997 (Campisi, , 2000 Chang et al., 1999) .
Over-expression of IGFBP-rP1/mac25 in the M12 prostate cancer cell line alters cell cycle kinetics and delays the cells in the G1 phase of the cell. High expressing IGFBP-rP1 clones demonstrated increased expression of p16 as well as decreased cyclin D1/cdk-4,6 kinase activity, resulting in hypophosphorylated pRb. Cyclin E and p27 levels were increased in these high expressing clones, while cyclin E/cdk-2 kinase activity was decreased, which can also delay cells in G1 by decreased pRb phosphorylation. Another mechanism by which IGFBP-rP1/mac25 may cause decreased tumor growth is by increasing apoptosis associated with increased cyclin A/cdk-2 kinase activity. Therefore, a delay in G1 and increased apoptosis are mechanisms by which IGFBP-rP1/mac25 decreases tumor growth in the M12 prostate cancer cell line.
Materials and methods
Materials
Tissue culture media, RPMI-1640, gentamicin, fungizone, geneticin (G418), and deoxyribonuclease were obtained from Life Technologies (Gibco-BRL) (Grand Island, NY, USA). Epidermal growth factor (EGF), dexamethasone, the additive ITS (5 mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml selenium), 5-Bromo-4-chloro-3-indolyl b-D galactopyranoside (X-Gal) and nocodazole were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT, USA). Tfx tm -50 Reagent was obtained from Promega (Madison, WI, USA). The BCA protein assay kit was from Pierce Biological (Rockford, IL, USA). Anti-cyclin A, E, p21, p16, and p27 sera were purchased from Oncogene Research Products (Calbiochem, San Diego, CA, USA). Anti-cyclin D1, anti-cyclin-dependent kinases (cdk) 2, 4, and 6, and anti-E2F-1 sera, Protein A/G Plus tm -agarose beads, and Rb fusion protein were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Anti-IGFBP-rP1/mac25 was a kind gift from E Wilson and RG Rosenfeld (Oregon Health Sciences University, Portland, OR, USA) (Wilson et al., 1997) . Histone H1 was purchased from Roche (Indianapolis, IN, USA). Horseradish peroxidaselinked sheep anti-mouse IgG, horseradish peroxidase-linked donkey anti-rabbit IgG, and Enhanced Chemiluminescence (ECL) detection reagents were purchased from Amersham (Arlington Heights, IL, USA). Each experiment was performed at least three separate times.
Cell culture
The derivation of the M12 cell line has been described previously (Bae et al., 1994 (Bae et al., , 1998 Jackson-Cook et al., 1996) . These cells stain positive to epithelial cytokeratin 8 and are androgen receptor (AR) negative. When the AR is expressed in these cells, they express prostate speci®c antigen (unpublished data). Cells were cultured in RPMI-1640 medium supplemented with 10 ng/ml epidermal growth factor, 0.02 mM dexamethasone, ITS, fungizone, and gentamicin at 378C under 5% CO 2 . All cells used in these experiments were mycoplasma free, as determined by the Mycoplasma PCR Primer Set (Stratagene, La Jolla, CA, USA).
Establishment of high expressing IGFBP-rP1/mac25 clones
Cells over-expressing IGFBP-rP1/mac25 were made as previously described (Sprenger et al., 1999) . M12 cells were transfected stably with either the empty pcDNA vector or the pc-IGFBP-rP1/mac25 construct and clones were selected in medium containing G418. RNA and media were collected for Northern and Western immunoblot analysis, respectively. RNA was probed with a 700 bp fragment of IGFBP-rP1/ mac25 and Western immunoblots were incubated with IGFBP-rP1/mac25 antiserum (Dr Ron Rosenfeld, OHSU, Portland, OR, USA). Three of the clones over-expressing IGFBP-rP1/mac25 (Ha, Hb, and Hc) and two control clones (M12pc 1 and M12pc 2 ) were chosen.
Senescence-associated b-galactosidase staining
Cells were grown to 60% con¯uence and then ®xed with 2% formaldehyde, 0.2% glutaraldehyde in PBS for 5 min at room temperature. Cells were then washed with PBS twice before adding the staining solution (1 mg/ml X-Gal; 40 mM citric acid/sodium phosphate buer, pH 6.0; 5 mM potassium ferrocyanide; 5 mM potassium ferricyanide; 150 mM sodium chloride; 2 mM magnesium chloride). Dishes were incubated at 378C (CO 2 free incubator) overnight and then analysed immediately for positive staining.
Flow cytometry using propidium iodide
Cells were grown to 80% con¯uence. Half of the dishes were then treated with the microtubule inhibitor nocodazole (5 mm) and half with plain RPMI. Following 20 h of treatment, 2x10 6 cells were pelleted and washed with PBS. Pellets were resuspended in cold 70% ethanol to a ®nal density of 1610 6 cells/ml, then pelleted and resuspended in 1 ml of DNA staining solution (PBS, pH 7.4, containing 0.1% Triton X-100, 0.1 mM EDTA (pH 7.4), 0.05 mg/ml RNase A (50 units/mg), 50 mg/ml propidium iodide). Cells were read on a Becton-Dickinson FACSCaliber at a wavelength of 488 nm. Data were collected and analysed using CellQuest and ModFit software, respectively.
Flow cytometry using FITC cell cycle antibodies
Cells were grown to 80% con¯uence and 2610 6 cells were collected. Cells were ®xed in either 100% ice-cold methanol (cyclin D1) or 80% ice-cold ethanol (cyclin A) (Juan and Darzynkiewicz, 1998 ) then washed once with each of the following: PBS, 1% BSA in PBS, and then 0.25% Triton X-100 in PBS. FITC cyclin antibodies were diluted 1 : 5 in 1% BSA in PBS and cells were incubated overnight at 48C, then pelleted and resuspended in 1ml DNA staining solution (0.5 mg/ml RNase A and 5 mg/ml PI in PBS). Cells were read and analysed as above.
Western immunoblots
Cells were grown to 80% con¯uence then synchronized in the G2/M phase of the cell cycle with 5 mM nocodazole (20 h treatment). Cells were lysed on ice for 10 min with lysis buer (50 mM HEPES (pH 7.8), 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1% Triton X-100). Protein concentrations of lysates were determined using the BCA kit (Pierce Biological, Rockford, IL, USA) and 50 mg of protein per sample were loaded. Samples were electrophoresed on 12% SDS-polyacrylamide gels then electro-blotted onto nitrocellulose. Western blots were incubated with one of the following antisera: cyclin D1, cyclin A, cyclin E, p21, p27, p16, cdk-2, -4, or -6. Bound antibody was detected using either a horseradish peroxidase-linked sheep anti-mouse or donkey anti-rabbit secondary antibody and the ECL detection system according to manufacturer's protocol. Buers and wash times were as suggested by the manufacturer, except that the nitrocellulose was ®rst washed with 10% hydrogen peroxide for 10 min. ScanAnalysis software was used for density scans of the immunoblots.
Cyclin-dependent kinase activity
Cells were grown to 80% and then lysed in IP buer (50 mM HEPES, pH 7.5; 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 1 mM DTT; 0.1% Tween-20) containing 10% glycerol and protease inhibitors (0.1 mM PMS; 10 mg.ml leupeptin; 20 U/ml aprotinin; 10 mM b-glycerophosphate; 1 mM NaF; 0.1 mM sodium orthovanadate). Samples were sheared with a 21G needle ®ve times and then centrifuged at 10 000 g for 5 min. Either anti-cyclin D1, anti-cyclin E, or anti-cyclin A (2 mg/ml) was added to lysates; total mix was then precipitated in a rotary shaker for 2 ± 6 h at 48C with protein A/G-PLUS agarose beads. Following incubation, beads were washed four times with IP buer and twice with either HEPES/DTT (for cyclin D-cdk-4,6 kinase assay) or histone was buer (25 mM Tris HCl, pH 7.5; 70 mM NaCl; 10 mM MgCl 2 ; 1 mM DTT). For the cyclin D/cdk-4,6 kinase assay, beads were resuspended in 30 ml of kinase buer (50 mM HEPES, pH 7.5; 10 mM MgCl 2 ; 1 mM DTT) containing 0.2 mg GST-pRb fusion protein, protease inhibitors (2.5 mM EGTA; 10 mM b-glycerophosphate; 1 mM NaF; 0.1 mM sodium orthovanadate), 20 mM ATP, and 10 mCi 32 P-gATP (6000 Ci/mmol) (NEN-DuPont, Wilmington, DE, USA). For the cyclin E/ cdk-2 or A/cdk-2 kinase assays, beads were resuspended in 30 ml histone wash buer containing 0.1 mg/ml Histone H1, 10 mM ATP, and 0.2 mCi/ml 32 P-gATP. These solutions were incubated for 30 min at 308C with occasional mixing; the reaction was terminated with 0.33 volume of 46 loading buer and samples boiled. Aliquots were run on a 10% SDS ± PAGE gel and analysed by autoradiography of the dried gel. Portions of the precipitates were run on separate SDS gels and probed with either anti-cyclin D1, E, or A and anti-cdk-2, -4, or -6 sera to con®rm the contents of the immunoprecipitated complexes.
